Appearance IIb exploration results of epratuzumab in patients with lupus to be presented at EULAR 2010
Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical comrades focused on developing monoclonal antibodies to present cancer and other severe diseases, today announced that clinical side results on epratuzumab, the anti-CD22 humanized monoclonal antibody licensed to UCB SA, Brussels, for the benefit of autoimmune malady indications, from the Include IIb swatting in patients with lupus, pass on be presented in four posters sessions and people published digest. These presentations choose hit at the 2010 annual Congress of the European Club allied with Against Rheumatism (EULAR), June 16 – 19, 2010, in Rome, Italy. In the aid half of 2010, UCB disposition tutor two Slant gradually introduce III studies of epratuzumab to go to the treatment of patients with modest and oppressive lupus.
The earmark of the notice sessions, followed during necessary findings, are listed lower than:
"Epratuzumab demonstrates clinically significant improvements in patients with steady to flinty systemic lupus erythematosus (SLE): Results from EMBLEM™, a Moment IIb study" [Saturday, June 19, 10:15 a.m. – 12:00 p.m.]
"Compared with placebo responder compute (21.1%), responder rates were statistically greater in epratuzumab 2400 mg (600 mg weekly) (45.9%;
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
